Anti-rtk antibodies and uses thereof

Agonistic antibodies targeting FGFR2IIIb, FGFR1IIIb, and DDR1a activate their signaling pathways, addressing the need for therapeutic agents that stimulate tissue repair and regeneration, effectively treating conditions like pulmonary and skin fibrosis.

HK40135148APending Publication Date: 2026-07-17CHUGAI PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026123473
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-29
Filing Date
2026-05-15
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

There is a significant medical need for the development of FGFR2 and FGFR1 agonists, as well as DDR1 agonists, to stimulate tissue repair and regeneration processes, as existing therapeutic agents primarily focus on inhibition rather than activation of these receptor tyrosine kinases.

Method used

Development of agonistic antigen-binding molecules, such as antibodies or fragments, that bind to FGFR2, FGFR1, and DDR1, specifically targeting FGFR2IIIb, FGFR1IIIb, and DDR1a, to activate their signaling pathways and promote tissue regeneration.

Benefits of technology

These molecules effectively activate FGFR2IIIb, FGFR1IIIb, and DDR1a signaling, providing therapeutic agents for treating tissue degenerative diseases and conditions like pulmonary and skin fibrosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000240_0000
    Figure 00000240_0000
  • Figure 00000242_0000
    Figure 00000242_0000
  • Figure 00000243_0000
    Figure 00000243_0000
Patent Text Reader

Abstract

The present invention relates to RTK agonists, in particular FGFR2b agonists, FGFR1b agonists, and DDR1 agonists, and methods of using the same.
Need to check novelty before this filing date? Find Prior Art